top of page
OPENPediatrics logo

Tumor Lysis Syndrome

Dr. Andrew Hong outlines the basics of tumor lysis syndrome, key laboratory and clinical findings, and how to prevent and manage hyperuricemia and electrolyte abnormalities due to TLS. He also identifies risk-factors for this syndrome and guides the learner through two detailed cases.

Released:

December 17, 2020

Audience:

Physicians

Learning Objectives

  • Define tumor lysis syndrome 

  • Understand the population of oncology patients at high risk for TLS 

  • Understand range of TLS therapies

  • Learn how to differentiate between MOA of allopurinol and rasburicase

  • Management of TLS

Author(s)

Andrew L. Hong, MD

Associate Professor, Department of Pediatrics | Emory University School of Medicine

Oncologist | Children's Healthcare of Atlanta

Instructor of Pediatrics | Dana-Farber/Boston Children's Cancer and Blood Disorders Center


Katherine R. Schlosser Metitri, MD

Pediatric Critical Care Specialist | Columbia University

Vice President, Operations | NewYork-Presbyterian Morgan Stanley Children’s Hospital


Sarah Marcley, RN, BSN
Medical Video Editor, OPENPediatrics | Boston Children's Hospital

Citation

Hong A, Marcley S, Schlosser K. Tumor Lysis Syndrome. 12/2020. Online Video. OPENPediatrics. https://learn.openpediatrics.org/learn/course/internal/view/elearning/4938/Tumor-Lysis-Syndrome.

bottom of page